Oct. 9 at 6:29 PM
$ECOR Earnings Preview - Scaling Bioelectronic Medicine and Wellness Platforms - We forecast FY26 revenue of
$40.5M (+35% YoY), narrowing the GAAP net loss to $(4.1M) and achieving positive EBITDA in 4Q26. At a
current EV of just
$29M, ECOR trades at ~1× EV/2025E revenue, well below peer averages of 3.5–4.0× for high-growth neuro-device companies. We reiterate our Buy rating and
$25 base-case price target, with a
$35 bull-case scenario reflecting 5× FY26E revenue.[Read More: https://hubs.ly/Q03M-kPx0]